Table 1 Patient cohort, clinical information, and cell enumeration.
From: Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
No. | Sex | Age | Type | Treatment | Time | Biopsy? | CTCs | Vol. | CTCs/mL | (PDL1 + ) | (PDL1−) | (UD) | WBCs/mL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P01 | M | 61 | squamous | Pembrolizumab | Pre | Y | 47 | 6 | 7.83 | 4.83 | 2.83 | 0.16 | 60 |
P02 | M | 59 | adeno. | Pembrolizumab | Pre | — | 35 | 6 | 5.83 | 5 | 0.83 | — | 6 |
P03 | F | 77 | adeno. | Ipilimumab, Nivolumab | Pre | — | 44 | 8 | 5.5 | 0 | 5.5 | — | 17 |
P04 | M | 67 | adeno. | Nivolumab | Pre | — | 28 | 6 | 4.67 | 2.83 | 1.83 | — | 56 |
P05 | F | 59 | adeno. | Pembrolizumab | Pre | Y | 19 | 6 | 3.17 | 1.5 | 1.66 | — | 18 |
P06 | F | 61 | adeno. | Erlotinib | Pre | Y | 24 | 8 | 3 | 2 | 1 | — | 1 |
P07 | F | 77 | adeno. | Pembrolizumab | Pre | Y | 19 | 9 | 2.11 | 0.33 | 1.77 | — | 11 |
P08 | F | 87 | adeno. | Ipilimumab, Nivolumab | Pre | — | 16 | 8 | 2 | 0 | 2 | — | 93 |
P09 | F | 91 | adeno. | Ipilimumab, Nivolumab | Pre | — | 10 | 8 | 1.25 | 0 | 1.25 | — | 18 |
P10 | M | 65 | adeno. | Ipilimumab, Nivolumab | Pre | — | 3 | 8 | 0.38 | 0 | 0.38 | — | 11 |
P11 | M | 66 | adeno. | Ipilimumab, Nivolumab | Pre | — | 2 | 6 | 0.33 | 0.16 | 0.16 | — | 19 |
P12 | F | 60 | adeno. | Ipilimumab, Nivolumab | Pre | — | 2 | 7 | 0.29 | 0 | 0.29 | — | 27 |
P13 | M | 65 | adeno. | Pembrolizumab | Pre | — | 1 | 6 | 0.17 | 0 | 0.17 | — | 23 |
P14 | M | 64 | adeno. | Pembrolizumab | Pre | — | 1 | 9.8 | 0.1 | 0.1 | 0 | — | 2 |
P15 | F | 75 | squamous | Ipilimumab, Nivolumab | Pre | — | 0 | 6 | 0 | 0 | 0 | — | 13 |
P16-1 | M | 62 | squamous | Avelumab | Pre | — | 20 | 6 | 3.33 | 3 | 0 | 0.33 | 10 |
P16-2 |  |  |  |  | On treatment | — | 5 | 8 | 0.62 | 0.5 | 0.12 | — | 10 |
P16-3 |  |  |  |  | On treatment | — | 11 | 6 | 1.83 | 1.83 | 0 | — | 5.3 |
P16-4 |  |  |  |  | On treatment | — | 31 | 8 | 3.87 | 3.5 | 0.12 | 0.25 | 14.9 |
P16-5 |  |  |  |  | On treatment | — | 6 | 6 | 1 | 1 | 0 | — | 10 |
P17 | M | 78 | adeno. | Pembrolizumab | Pre | — | 3 | 8 | 0.38 | 0.125 | 0.25 | — | 13 |
P18 | M | 82 | adeno. | Ipilimumab, Nivolumab | After 1st dose | — | 1 | 6 | 0.17 | 0.17 | 0 | — | 19 |
P19-1 | M | 69 | squamous | Pembrolizumab | After 1st dose | — | 4 | 6 | 0.67 | 0 | 0.67 | — | 9.33 |
P19-2 |  |  |  |  | On treatment | — | 6 | 8 | 0.75 | 0.5 | 0.25 | — | 3.75 |
P19-3 |  |  |  |  | On treatment | — | 1 | 8 | 0.12 | 0 | 0.12 | — | 17.62 |
P19-4 |  |  |  |  | On treatment | — | 58 | 6 | 9.67 | 1.33 | 8.33 | — | 16.83 |
P19-5 |  |  |  |  | On treatment | — | 8 | 8 | 1 | 0.62 | 0.25 | 0.12 | 7.5 |
P19-6 |  |  |  |  | After treatment | — | 1 | 6 | 0.17 | 0.17 | 0 | — | 20.5 |
P20 | M | 76 | adeno. | Pembrolizumab | On treatment | — | 43 | 6 | 7.16 | 0.16 | 6.83 | 0.16 | 30 |
P21 | F | 51 | adeno. | Avelumab | On treatment | — | 24 | 6 | 4 | 0.5 | 3.5 | — | 20 |
P22 | M | 74 | squamous | Pembrolizumab | On treatment | — | 2 | 8 | 0.25 | 0 | 0.25 | — | 5 |
HD01 | F | 57 | Healthy | — | — | — | 2 | 4 | 0.5 | — | — | — | 14 |
HD02 | M | 55 | Healthy | — | — | — | 5 | 4 | 1.25 | — | — | — | 30.75 |
HD03 | M | 20 | Healthy | — | — | — | 0 | 2 | 0 | — | — | — | 18.5 |
HD04 | M | 23 | Healthy | — | — | — | 2 | 6 | 0.33 | — | — | — | 12 |
HD05 | M | 35 | Healthy | — | — | — | 5 | 6 | 0.83 | — | — | — | 19.3 |
HD06 | F | 69 | Healthy | — | — | — | 6 | 6 | 1 | — | — | — | 17.3 |
HD07 | F | 77 | Healthy | — | — | — | 2 | 6 | 0.33 | — | — | — | 27.6 |
HD08 | F | 41 | Healthy | — | — | — | 4 | 6 | 0.66 | — | — | — | 21.3 |
HD09 | M | 69 | Healthy | — | — | — | 1 | 6 | 0.16 | — | — | — | 29 |
HD10 | F | 60 | Healthy | — | — | — | 3 | 6 | 0.5 | — | — | — | 13.83 |
